Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Liberty Global Ltd Class C (LBTYK) vs Smith & Nephew plc (SNN) Price & Performance

Liberty Global Ltd Class CTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Liberty Global Ltd Class C vs Smith & Nephew plc — how do they compare? Liberty Global Ltd Class C trades at $9.98 (market cap $3.48B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Smith & Nephew plc is far larger — about 3.6× Liberty Global Ltd Class C's market cap, and Smith & Nephew plc pays a 2.64% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.

LBTYKSNN
Market Cap
$3.48B$12.50B
Sector
TechnologyHealth
52-Week High
$12.67$38.70
52-Week Low
$9.59$28.73
Enterprise Value
$10.13B$15.53B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Liberty Global Ltd Class C

LBTYK trades at $10.24, down 2.38% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion in 2025, though operating cash flow remains positive at $1.21 billion. Recent news highlights the completion of the VodafoneZiggo buyout and preparations for a 2027 Ziggo Group listing, a key strategic move.

Despite deep losses, the stock appears undervalued on price-to-sales (0.7) and price-to-book (0.37) metrics. Analyst sentiment is strongly bullish (69% buy ratings), seeing upside from asset monetization and the Ziggo spin-off. Key risks include persistent negative margins and execution of the separation plan.

Smith & Nephew plc

SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.

The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.

Returns comparison

Trailing returns across standard periods

About Liberty Global Ltd Class C

Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.

Read more on LBTYK

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN